TLR4 and autoimmune polyendocrinopathy: In APS patients, mononuclear cells overexpress TLR2 and TLR4, which mediate aPL-induced vascular anomalies [36,37,38], pointing at these receptors as therapeutic targets to prevent aPLs-induced thrombosis in APS.